Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: A systematic review

RL Mulder, LCM (Leontien) Kremer, HM van Santen, JL Ket, ASP van Trotsenburg, CCE Koning, AYN Schouten-van Meeteren, HN Caron, S.J.C.M.M. Neggers, EC van Dalen

Research output: Contribution to journalArticleAcademicpeer-review

74 Citations (Scopus)

Abstract

Background: Growth hormone deficiency (GHD) is usually the first and most frequent endocrine problem occurring after cranial radiotherapy (CRT). The aim of this systematic review was to evaluate the existing evidence of the prevalence and risk factors of radiation-induced GHD in childhood cancer survivors. Methods: MEDLINE, EMBASE and CENTRAL were searched for studies reporting on radiation-induced GHD in childhood cancer survivors. Information about study characteristics, prevalence and risk factors was abstracted and the quality of each study was assessed. A meta-regression analysis was performed. Results: The prevalence of radiation-induced GHD was estimated in 33 studies. Most studies had methodological limitations. The prevalence varied considerably between 0% and 90.9%. Selecting only the studies with adequate peak GH cut-off limits (<5 mu g/L) resulted in 3 studies. In these studies the prevalence ranged from 29.0% to 39.1%, with a pooled prevalence of 35.6%. Higher CRT dose and longer follow-up time have been suggested to be the main risk factors of GHD by studies included in this review. The meta-regression analysis showed that the wide variation in the prevalence of GHD could be explained by differences in maximal CRT dose. Conclusions: GHD is a frequent consequence after CRT in childhood cancer survivors. The prevalence of radiation-induced GHD ranged from 29.0% to 39.1% when selecting only studies with adequate peak GH cut-off limits. Higher CRT dose and longer follow-up time are the main risk factors. More well-designed studies are needed to accurately estimate the prevalence of GHD and to define the exact CRT threshold dose. (C) 2009 Elsevier Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)616-632
Number of pages17
JournalCancer Treatment Reviews
Volume35
Issue number7
DOIs
Publication statusPublished - 2009

Research programs

  • EMC MM-01-39-01

Cite this